Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Inventory: 2009-2025

Historic Inventory for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Sep 2025 value amounting to $2.9 million.

  • Cumberland Pharmaceuticals' Inventory fell 34.92% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year decrease of 34.92%. This contributed to the annual value of $4.0 million for FY2024, which is 13.22% down from last year.
  • Cumberland Pharmaceuticals' Inventory amounted to $2.9 million in Q3 2025, which was down 8.94% from $3.2 million recorded in Q2 2025.
  • In the past 5 years, Cumberland Pharmaceuticals' Inventory ranged from a high of $10.9 million in Q2 2023 and a low of $2.9 million during Q3 2025.
  • In the last 3 years, Cumberland Pharmaceuticals' Inventory had a median value of $4.3 million in 2024 and averaged $5.6 million.
  • Its Inventory has fluctuated over the past 5 years, first soared by 32.47% in 2021, then slumped by 60.63% in 2024.
  • Quarterly analysis of 5 years shows Cumberland Pharmaceuticals' Inventory stood at $8.4 million in 2021, then climbed by 17.01% to $9.9 million in 2022, then slumped by 53.27% to $4.6 million in 2023, then dropped by 13.22% to $4.0 million in 2024, then plummeted by 34.92% to $2.9 million in 2025.
  • Its Inventory stands at $2.9 million for Q3 2025, versus $3.2 million for Q2 2025 and $4.1 million for Q1 2025.